Details for Patent: 11,072,614
✉ Email this page to a colleague
Which drugs does patent 11,072,614 protect, and when does it expire?
Patent 11,072,614 protects SEPHIENCE and is included in one NDA.
This patent has thirty-eight patent family members in thirteen countries.
Summary for Patent: 11,072,614
| Title: | Polymorphs of sepiapterin and salts thereof |
| Abstract: | Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria. |
| Inventor(s): | Daniel E. Levy |
| Assignee: | PTC Therapeutics MP Inc |
| Application Number: | US16/464,771 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 11,072,614
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ptc Therap | SEPHIENCE | sepiapterin | POWDER;ORAL | 219666-002 | Jul 28, 2025 | RX | Yes | Yes | 11,072,614 | ⤷ Start Trial | Y | TREATMENT OF HYPERPHENYLALANINEMIA (HPA) IN ADULT AND PEDIATRIC PATIENTS WITH SEPIAPTERIN-RESPONSIVE PHENYLKETONURIA (PKU) BY ADMINISTERING SEPIAPTERIN | ⤷ Start Trial | |||
| Ptc Therap | SEPHIENCE | sepiapterin | POWDER;ORAL | 219666-001 | Jul 28, 2025 | RX | Yes | No | 11,072,614 | ⤷ Start Trial | Y | TREATMENT OF HYPERPHENYLALANINEMIA (HPA) IN ADULT AND PEDIATRIC PATIENTS WITH SEPIAPTERIN-RESPONSIVE PHENYLKETONURIA (PKU) BY ADMINISTERING SEPIAPTERIN | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,072,614
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017366879 | ⤷ Start Trial | |||
| Australia | 2022203481 | ⤷ Start Trial | |||
| Australia | 2024200344 | ⤷ Start Trial | |||
| Brazil | 112019010222 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
